双嘧达莫联合舒血宁治疗超溶栓时间窗急性脑梗死的临床效果

Clinical effect of Dipyridamole combined with Shuxuening in the treatment of acute cerebral infarction over thrombolysis time window

目的探讨双嘧达莫联合舒血宁治疗超溶栓时间窗急性脑梗死的临床效果。方法选择2018年9月至2020年3月庄河市中心医院神经内科收治的96例超溶栓时间窗急性脑梗死患者作为研究对象,采用随机数字表法分为参照组(48例)与联合组(48例)。参照组采用常规对症治疗+双嘧达莫静滴治疗方法,联合组采用常规对症治疗+双嘧达莫+舒血宁莫静滴治疗方法。比较两组的神经功能、肢体功能、日常生活活动能力、疗效、凝血指标改善情况及不良反应发生率。结果联合组患者治疗后美国国立卫生研究院卒中量表(NIHSS)评分低于参照组,差异有统计学意义(P<0.05),联合组Fugl-Meyer运动功能评估量表(FMAS)及日常生活活动能力量表(ADL)评分高于参照组,差异有统计学意义(P<0.05);联合组治疗总有效率高于参照组,差异有统计学意义(P<0.05);联合组治疗后凝血酶原时间(PT)、凝血酶时间(TT)、活化部分凝血活酶时间(APTT)长于参照组,以及纤维蛋白原(FIB)水平低于参照组,差异有统计学意义(P<0.05);两组用药后不良反应发生率比较,差异无统计学意义(P>0.05)。结论双嘧达莫联合舒血宁用药在超溶栓时间窗急性脑梗死患者治疗中应用具有显著效果,其神经功能、肢体功能、生活活动能力及凝血指标均得到显著改善,且不良反应相对较少、安全可靠。

Objective To investigate the clinical effect of Dipyridamole combined with Shuxuening in the treatment of acute cerebral infarction over thrombolysis time window.Methods A total of 96 patients with acute cerebral infarction over thrombolysis time window in Zhuanghe Central Hospital,Liaoning Province from September 2018 to March 2020 were selected as the research subjects.They were divided into a reference group(48 cases)and a joint group(48 cases)according to the random number table method.Patients in the reference group were treated with conventional symptomatic treatment+Dipyridamole via intravenous drips,while patients in the joint group were treated with conventional symptomatic treatment+Dipyridamole+Shuxuening via intravenous drips.Neurological function,limb function,daily live activity ability,efficacy,improvement of coagulation indexes and incidence of adverse reactions were compared between the two groups.Results After treatment,the scores of National Institutes of Health stroke scale(NIHSS)in the joint group were lower than those in the reference group,with statistically significant different(P<0.05).The scores of Fugl-Meyer assessment scale(FMAS)and activity of daily living scale(ADL)in the joint group were higher than those in the reference group,the differences were statistically significant(P<0.05).The total effective rate of the joint group was higher than that of the reference group,with statistically significant different(P<0.05).After treatment,the prothrombin time(PT),thrombin time(TT),activated partial thromboplastin time(APTT)in the joint group were longer than those in the reference group,and fibrinogen(FIB)in the joint group was lower than that in the reference group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of dipyridamole combined with Shuxuening in the treatment of acute cerebral infarction patients over thrombolysis time window has a significant effect,and the neurological function,limb function,life activity ability and coagulation indexes have been significantly improved,with few adverse reactions,which is safe and reliable.